Core Insights - Aipeng Medical (300753.SZ) has multiple products in the brain-computer interface (BCI) field that have been commercialized, including an anesthetic depth monitor for perioperative brain state monitoring and a treatment system for refractory insomnia [1] - The company has a stake in Changzhou Ruishen'an Medical, which has received approval for its implanted deep brain stimulation device [1] - Currently, the company does not have any products applying for the special review process for innovative medical devices [1] Industry Developments - The first invasive brain-computer interface product, a "wireless implanted brain-computer interface system" developed by Shanghai Ladder Medical Technology Co., has entered the special review process of the National Medical Products Administration (NMPA), marking a significant step in the industrialization of this cutting-edge technology in China [3] - This development indicates a shift from clinical validation to market access for BCI products in China, highlighting the growing importance of this technology in the medical field [3]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，爱朋医疗(300753)11月13日在投资者关系平台上答复投资者关心的问题。 投资者提问：工信部：中试平台应聚焦培育壮大新兴产业、布局建设未来产业等任务 加快产业科技创 新成果向现实生产力转化】智通财经11月11日电，工业和信息化部办公厅发布《制造业中试平台建设指 引（2025版）》。其中提出，中试平台应围绕加快推进新型工业化、建设制造强国战略需求，聚焦改造 提升传统产业、培育壮大新兴产业、布局建设未来产业的任务，加快产业科技创新成果向现实生产力转 化。在脑机接口、贵如何在脑机接口大发展？ 爱朋医疗回复：您好，国家政策正在助力脑机接口行业加速发展。公司将持续巩固自身技术平台，积累 和提升相关核心技术和核心竞争力，在脑机接口领域持续推进围术期脑状态监测、多动症、睡眠疾病诊 治、癫痫等精神类疾病诊疗的临床创新应用。谢谢。 ...

Core Viewpoint - The company is actively promoting the application of new generation information technologies in the healthcare sector, particularly in brain-computer interface technology and various medical devices [1] Group 1: Healthcare Sector Applications - The company is integrating big data, IoT, brain-computer interfaces, and medical robots to innovate healthcare applications such as health consulting, remote medical services, and medication review [1] - The company has developed a treatment system for refractory insomnia, designed to meet clinical needs in sleep diagnosis and treatment [1] - A multimodal ADHD behavior training system has been introduced, utilizing scientific EEG monitoring and multimodal intervention training to help children improve attention-deficit behaviors [1] Group 2: Elderly Care and Assistance - In the elderly care and assistance sector, the company has invested in Changzhou Ruishen'an to develop and produce medical devices related to brain nerve regulation and intracranial electrodes [1] - The company offers a range of registered products, including disposable intracranial electrodes (SEEG), implantable vagus nerve stimulators (VNS), implantable rechargeable spinal cord stimulators (SCS), and deep brain stimulation systems (CNS) [1] - These products are applicable in treating epilepsy, pain management, and Parkinson's disease [1]

Healthcare Policy - National Healthcare Security Administration held a series of discussions on the adjustment of the disease-based payment grouping scheme 3.0, involving over 70 representatives from medical institutions and industry associations [1] Drug and Medical Device Approvals - Shijiazhuang Pharmaceutical Group's application for the listing of Pertuzumab injection has been accepted by the National Medical Products Administration, targeting HER2-positive breast cancer [1] - Huason Pharmaceutical received a registration certificate for its special medical purpose formula food, Ganyimei®, designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders [2] - United Imaging Healthcare's subsidiary obtained a medical device registration certificate for its color Doppler ultrasound diagnostic system, enhancing its product range across various market segments [3] - Yiling Pharmaceutical's application for the listing of Memantine Hydrochloride, a drug for treating moderate to severe Alzheimer's disease, has been approved [4] - Zhifei Biological's clinical trial application for a freeze-dried varicella inactivated vaccine has been accepted by the National Medical Products Administration [10] - Changchun High-tech's subsidiary received approval for a clinical trial of an acellular pertussis-diphtheria-tetanus combined vaccine for adolescents and adults [11] Capital Market Activities - Peking University Pharmaceutical announced the release of 34,615,386 shares from pledge, representing 51.52% of the pledged shares and 5.81% of the total share capital [5] - Kelun Pharmaceutical received approval for a registration of 4 billion yuan in ultra-short-term financing bonds, with a validity period of 2 years [6][7] - Baili Tianheng decided to delay its global offering and listing of H-shares due to current market conditions [8] - Aipeng Medical announced a plan for a shareholder to reduce holdings by up to 1% of total shares, citing personal funding needs [12] - Hendi Pharmaceutical's shareholders plan to collectively reduce their holdings by up to 2.33% of total shares for personal financial planning [13] Financial Adjustments - Baihua Pharmaceutical plans to use 1.91 billion yuan from its capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [14]

Core Viewpoint - The major shareholder of Aipeng Medical, Beijing Zhanghong Private Fund Management Co., Ltd., plans to reduce its holdings in the company due to funding needs, with a total reduction of up to 252,090 shares, which is approximately 2.1% of the total share capital [1][2]. Group 1: Shareholder Reduction Plan - The shareholder, Zhanghong Selected No. 1 Private Securities Investment Fund, holds 5.6% of the company's total shares and intends to reduce its holdings by up to 126,050 shares through centralized bidding and another 126,050 shares through block trading [2]. - The reduction is based on market prices and is expected to take place within three months after the announcement [2]. Group 2: Financial Performance - In the first three quarters of the year, Aipeng Medical reported a revenue of 252 million yuan, a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of -11.48 million yuan, a decline of 401.64% [3]. - The third quarter showed a net profit of 7.89 million yuan, reflecting a year-on-year increase of 255.22% [3]. Group 3: Company Background - Aipeng Medical focuses on pain management and upper respiratory tract management, while also expanding into intelligent medical device ecosystems and innovative businesses such as brain-machine interfaces and rapid rehabilitation [3]. - The company has a stake in Changzhou Ruishen'an Medical Device Co., Ltd., which specializes in the research, production, and sales of medical devices related to brain nerve regulation [3].

Core Viewpoint - Aipeng Medical (300753.SZ) experienced a significant price fluctuation, rising over 16% before a midday drop of nearly 6%, with its stock price falling below 29 yuan [1] Summary by Relevant Sections Shareholder Actions - Shareholder Beijing Zhanghong Private Equity Fund Management Co., Ltd. plans to reduce its holdings by no more than 2.52 million shares, which represents up to 2% of the company's total share capital [1] - The company has announced a total of five share reduction plans in the past three years [1] Market Reaction - The stock's midday decline followed a substantial increase earlier in the trading session, indicating volatility in investor sentiment [1] - The announcement of the share reduction may have contributed to the stock's price drop [1]

Group 1: Company Announcements - Zhejiang Dongri clarifies that it is not involved in "brain-computer interface" business [1] - Sanyuan Co. introduces seasonal product "milk candy hawthorn," which has a minimal revenue contribution [1] - Century Huatong plans to repurchase shares worth between 500 million to 1 billion [1] Group 2: Project Investments - Yongrong Co. intends to establish a subsidiary to build a 100 MW photovoltaic power station [1] - Weigao Medical plans to invest in a production base for all-cotton water-jet non-woven fabric [1] - Fuchun Environmental plans to invest in a combined heat and power project in Yicheng, Hubei [1] - Haibo Co. aims to invest in high-end components for flywheel energy storage [1] Group 3: Contract Awards - Longjian Co. wins a construction project worth 483 million [1] - Zhejiang Jiaoke is part of a consortium that aims to win a new urbanization project along the Fuchun River [1] - Dash Smart wins the intelligent project for the new Hong Kong Port inspection building [1] Group 4: Equity Transfers - Aerospace Intelligent Equipment plans to transfer 100% equity of its wholly-owned subsidiary Hangzhou Xuanyu [1] Group 5: Shareholding Changes - Aoxing Packaging's controlling shareholder plans to reduce holdings by up to 1.91% [2] - Aipeng Medical's Zhang Hong selected No. 1 intends to reduce holdings by up to 2% [2] - Ruimaite's senior executive Chen Bei plans to reduce holdings by up to 1.76% [3] - Changlian Co.'s director and general manager Xu Feng plans to reduce holdings by up to 206,520 shares [3] Group 6: Other Notable Events - Peking University Pharmaceutical's chairman and president Xu Xiren has been arrested on criminal charges [3] - Haibo Co. signs a strategic cooperation agreement with CATL, committing to procure no less than 200 GWh of electricity over the next three years [3]

Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - Aipeng Medical (300753) announced that its shareholder, Beijing Zhanghong Private Equity Fund Management Co., Ltd. - Zhanghong Selected No. 1 Private Securities Investment Fund, plans to reduce its stake by up to 2% of the company's shares [1] Summary by Category Shareholder Actions - Zhanghong Selected No. 1 plans to reduce its holdings by no more than 1.26 million shares, which represents 1% of the total share capital of the company, through centralized bidding within three months after a 15 trading day period following the announcement [1] - Additionally, the fund intends to reduce another 1.26 million shares, also representing 1% of the total share capital, through block trading within the same timeframe [1] Current Holdings - As of the announcement, Zhanghong Selected No. 1 holds 7.058 million shares, accounting for 5.6% of the company's total share capital [1]